The Transcription Factor Interferon Regulatory Factor 1 Is  Expressed after Cerebral Ischemia and Contributes to  Ischemic Brain Injury by Iadecola, Costantino et al.
 
719
 
The Journal of Experimental Medicine • Volume 189, Number 4, February 15, 1999 719–727
http://www.jem.org
 
The Transcription Factor Interferon Regulatory Factor 1 Is 
Expressed after Cerebral Ischemia and Contributes to 
Ischemic Brain Injury
 
By Costantino Iadecola,
 
*
 
 Cindy A. Salkowski,
 
‡
 
 Fangyi Zhang,
 
*
 
Tracy Aber,
 
*
 
 Masao Nagayama,
 
*
 
 Stefanie N. Vogel,
 
‡
 
and M. Elizabeth Ross
 
*
 
From the 
 
*
 
Department of Neurology, University of Minnesota, Minneapolis, Minnesota 55455; and 
the 
 
‡
 
Department of Microbiology and Immunology, Uniformed Services University of the Health 
Sciences, Bethesda, Maryland 20814
 
Summary
 
The transcription factor interferon regulatory factor 1 (IRF-1) is involved in the molecular
mechanisms of inflammation and apoptosis, processes that contribute to ischemic brain injury.
In this study, the induction of IRF-1 in response to cerebral ischemia and its role in ischemic
brain injury were investigated. IRF-1 gene expression was markedly upregulated within 12 h
 
of occlusion of the middle cerebral artery in C57BL/6 mice. The expression reached a peak 4 d
after ischemia (6.0 
 
6
 
 1.8-fold;
 
 P 
 
, 
 
0.001) and was restricted to the ischemic regions of the
brain. The volume of ischemic injury was reduced by 23 
 
6
 
 3% in IRF-1
 
1/2
 
 and by 46 
 
6
 
 9%
in IRF-1
 
2/2
 
 mice (
 
P
 
 , 
 
0.05). The reduction in infarct volume was paralleled by a substantial
attenuation in neurological deficits. Thus, IRF-1 is the first nuclear transacting factor demon-
strated to contribute directly to cerebral ischemic damage and may be a novel therapeutic target
in ischemic stroke.
Key words: cerebral ischemia • interferon regulatory factor 1 null mice • gene expression • 
neuroprotection • reverse transcription polymerase chain reaction
 
I
 
n experimental animals, as in humans, focal cerebral is-
chemia is associated with an intense inflammatory reac-
tion that contributes to the secondary progression of
ischemic brain injury (for review see references 1, 2). Within
hours after the insult, cytokines and chemokines are pro-
duced in the ischemic brain (3–7). Cytokines contribute to
the enhanced expression of adhesion molecules on cerebral
endothelial cells, which, in turn, leads to adhesion of circu-
lating neutrophils to cerebral endothelial cells (8–14). Neu-
trophils and, subsequently, monocytes migrate through the
vessel wall and invade the injured brain (15–17). Inflamma-
tion-related enzymes, such as the “immunologic” isoform
of nitric oxide synthase (iNOS) and cyclooxygenase-2, are
induced in the postischemic brain (18–22). Furthermore,
genes involved in programmed cell death, such as 
 
p53
 
, 
 
Bax
 
,
and 
 
bcl2
 
, are upregulated (23–26), whereas caspases, the
cysteine proteases thought to be the effectors of pro-
grammed cell death, are activated (27, 28).
The molecular mechanisms by which this complex ge-
nomic response is orchestrated have not been elucidated.
Although a number of transcription factors are activated af-
ter cerebral ischemia (29–32), no single transcription factor
has been conclusively linked to the mechanisms that under-
lie tissue damage (for example see reference 33). One of the
transcription factors that is important for gene expression
 
during inflammation is interferon regulatory factor (IRF)-1
 
1
 
(for review see reference 34). IRF-1 was originally de-
scribed as one of the transcriptional activators responsible
for expression of interferon and interferon-inducible genes
(35). More recently, the view has emerged that IRF-1 is
involved in multiple functions including cellular responses
to inflammation and programmed cell death (for review see
reference 36). Therefore, it is conceivable that IRF-1 plays
a role in gene expression after cerebral ischemia.
In this study, we investigated the potential contribution
of IRF-1 to cerebral ischemic damage. Specifically, we
sought to establish whether IRF-1 is upregulated after ce-
rebral ischemia and, if so, whether its expression plays a
central role in the mediation of tissue damage. Our studies
demonstrate that occlusion of the middle cerebral artery
 
1
 
Abbreviations used in this paper:
 
 CBF, cerebral blood flow; HPRT, hypo-
xanthine-guanine phosphoribosyl transferase; IRF-1, interferon regula-
tory factor 1, iNOS, inducible nitric oxide synthase; MCA, middle cere-
bral artery; NO, nitric oxide. 
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(MCA) in mice leads to upregulation of IRF-1 mRNA
within the ischemic region. Furthermore, IRF-1
 
2/2
 
 mice
fail to express IRF-1 after cerebral ischemia and exhibit an
attenuation of brain injury after MCA occlusion. The effect
is more pronounced in IRF-1
 
2/2
 
 than in IRF-1
 
1/2
 
 mice,
and is associated with improved neurological outcome.
The findings demonstrate that IRF-1 is involved in the
evolution of brain damage after cerebral ischemia. IRF-1
represents the first transcription factor for which a link with
ischemic brain injury has been established.
 
Materials and Methods
 
Animals
 
All animal procedures were approved by the Animal Care
Committee of the University of Minnesota. Mice with a targeted
mutation in the IRF-1 gene (homozygous [
 
2/2
 
] mice and their
heterozygous [
 
1/2
 
] littermates) were originally obtained from
Dr. T.W. Mak (Amgen Institute, Toronto, Canada) and had
been back-crossed to C57BL/6 mice three to five times. Mice
were subsequently bred in a virus antibody-free facility at the
Uniformed Services University of the Health Sciences. The IRF-
1
 
2/2
 
 colony was maintained by mating IRF-1
 
2/2
 
 mice to either
IRF-1
 
2/2
 
 or IRF-1
 
1/2
 
 mice. An IRF-1 wild-type (
 
1
 
/
 
1
 
) colony
was maintained by mating IRF-1
 
1/1
 
 mice that were derived from
heterozygous mating of either IRF-1
 
1/1
 
 or IRF-1
 
1/2
 
 mice. To
prevent the background of the IRF-1
 
2/2
 
 and IRF-1
 
1
 
/
 
1
 
 colonies
from straying, all new breeding pairs were the progeny of IRF-
1
 
1/2
 
 to IRF-1
 
1/2
 
 matings. The genotype of all IRF-1 mice was
determined by PCR using primers and methods described previ-
ously (37). The IRF-1 primers amplify a 300-bp sequence from
IRF-1
 
1/1
 
 and IRF-1
 
1/2
 
 genomic DNA, whereas neo primers
amplify a product of 525 bp, present only in IRF-1
 
1/2
 
 and IRF-
1
 
2/2
 
 mice. C57BL/6 mice were used as controls in some experi-
ments and were obtained from The Jackson Laboratory.
 
Induction of Focal Cerebral Ischemia
 
Focal cerebral ischemia was produced by occlusion of the
MCA as previously described (20). Mice were anesthetized with
2% halothane in 100% oxygen. Body temperature was main-
tained at 37 
 
6
 
 0.5
 
8
 
C by a thermostatically controlled infrared
lamp. A 2-mm hole was drilled in the inferior portion of the
temporal bone to expose the left MCA. The MCA was elevated
and cauterized distal to the origin of the lenticulostriate branches.
Mice in which the MCA was exposed but not occluded served as
sham-operated controls. Wounds were sutured and mice were al-
lowed to recover and returned to their cages. Rectal temperature
was controlled until mice regained full consciousness. Mice were
killed at different time points after MCA occlusion for determi-
nation of IRF-1 mRNA or measurement of infarct size (see be-
low).
 
Determination of IRF-1 mRNA by Reverse
Transcription PCR
 
C57BL/6 and IRF-1
 
1/1
 
, IRF-1
 
1/2
 
, and IRF-1
 
2/2
 
 mice were
killed various times after MCA occlusion (
 
n
 
 
 
5 
 
6–12/time point).
As described in detail elsewhere (20), a 2-mm-thick coronal brain
slice was cut at the level of the optic chiasm and the infarcted
cortex was dissected using the corpus callosum as a ventral land-
mark. The homotopic region of the contralateral cortex was also
 
sampled. Total RNA was extracted, and the integrity of the
RNA was determined on denaturing formaldehyde gels. IRF-1
and hypoxanthine-guanine phosphoribosyl transferase (HPRT)
mRNA were detected by reverse transcription PCR as described
in detail previously (37, 38). The primer and probe sequences for
IRF-1 and HPRT have been published previously (37–39). Cy-
cle numbers for IRF-1 and HPRT were 29 and 23, respectively.
The IRF-1 primers amplify a 148-bp fragment from cDNA. Af-
ter agarose gel electrophoresis, amplified products were trans-
ferred to Hybond N
 
1
 
 membranes (Amersham) by standard
Southern blotting techniques. Blots were hybridized with an
internal oligonucleotide probe. Labeling of the probe and subse-
quent detection was carried out with the enhanced chemi-
luminescence system (ECL; Amersham) according to the manu-
facturer’s instructions. Chemiluminescent signals were quantified
using a scanner and imaging software (NIH Image; National In-
stitutes of Health). The relative gene expression in test samples
was assessed by linear regression analysis of a standard curve gen-
erated from a cDNA sample known to be positive for the gene of
interest. Data were normalized to the housekeeping gene HPRT.
 
Determination of Infarct Volume
 
Mice were killed 4 d after MCA occlusion. Brains were re-
moved and frozen in cooled isopentane (
 
2
 
30
 
8
 
C). Coronal fore-
brain sections (30-
 
m
 
m-thick) were serially cut in a cryostat, col-
lected at 150-
 
m
 
m intervals, and stained with thionin for
determination of infarct volume by an image analyzer (MCID,
Imaging Research Inc.; reference 20). To factor out the contri-
bution of ischemic edema to the total volume of the lesion, in-
farct volume in cerebral cortex was corrected for swelling (see
reference 20 for details). The correction method is based on the
determination of ischemic swelling by comparing the volume of
ischemic and nonischemic hemispheres (40).
 
Determination of Neurological Deficits
 
Neurological deficits were assessed by a neurological scoring
system widely used in mice (for examples see references 41, 42)
that has been described previously (20). The examiner was not
aware of the identity of the mice. The neurological scores were as
follows: 0, normal motor function; 1, flexion of torso and con-
tralateral forelimb upon lifting the mouse by the tail; 2, circling to
the contralateral side when holding the mouse by the tail on a flat
surface, but normal posture at rest; 3, leaning to the contralateral
side at rest; 4, no spontaneous motor activity (20). Mice were
evaluated before MCA occlusion and at 24-h intervals up to 4 d
after MCA occlusion.
 
Monitoring of Cerebral Blood Flow
 
Techniques used for monitoring cerebral blood flow (CBF) in
mice have been described in detail previously (20). Mice were
anesthetized with halothane (maintenance 1%) and the femoral
artery and trachea were cannulated. Mice were artificially venti-
lated with an oxygen-nitrogen mixture by a mechanical ventila-
tor (SAR-830; CWI Inc.). The inspiration time was set at 0.1 s,
the respiratory rate at 120/min, and the inspiratory flow at 
 
z
 
250
ml/min. The oxygen concentration in the mixture was adjusted
to maintain arterial pO
 
2
 
 between 150 and 170 mmHg. End-tidal
CO
 
2
 
 was continuously monitored using a CO
 
2
 
 analyzer (Capstar-
100; CWI Inc.) and maintained at 2.6–2.7%, which corresponds
to a pCO
 
2
 
 of 33–35 mmHg (20).
 
MCA Occlusion.
 
For monitoring changes in CBF produced
by MCA occlusion, two laser-Doppler flow probes (Vasamedic) 
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were placed through burr holes placed in the center (3.5 mm lat-
eral to the midline and 1 caudal to bregma) and the periphery
(1.5 mm lateral to the midline and 1.7 mm rostral to lambda) of
the ischemic territory (20, 43). The location of the probe was se-
lected in preliminary experiments to correspond to the region of
brain that is spared from infarction in the IRF-1–deficient mice.
After placement of the probes, the MCA was occluded and CBF
was monitored for 90 min. CBF data are expressed as percentage
of the preocclusion value.
 
Cerebrovascular Reactivity to Hypercapnia.
 
Techniques for test-
ing cerebral vascular reactivity to hypercapnia in mice were simi-
lar to those previously described (20). Mice were anesthetized
and instrumented as described above. CBF was continuously
monitored in the frontoparietal cortex with a laser-Doppler
probe. After stabilization of arterial pressure and blood gases, CO
 
2
 
was introduced into the circuit of the ventilator and the increase
in CBF produced by hypercapnia was monitored. CO
 
2
 
 adminis-
tration was discontinued after the CBF increase reached a plateau
(usually 2–3 min).
 
Data Analysis
 
Data in text and figures are expressed as means 
 
6
 
 SEM. Multi-
ple comparisons were evaluated statistically by the analysis of
variance and Tukey’s test. Two-group comparisons were ana-
lyzed by the two-tailed Student’s 
 
t
 
 test for independent samples.
Neurological scores were analyzed by the Kruskal-Wallis analysis
of variance followed by the Tukey-Kramer test (Systat) (20). For
all procedures, probability values of 
 
,
 
0.05 were considered sta-
tistically significant.
 
Results
 
Postischemic IRF-1 mRNA Expression in C57BL/6 and
IRF-1 Mice.
 
We first sought to determine if focal cerebral
ischemia enhances IRF-1 mRNA expression. In C57BL/6
mice, MCA occlusion was associated with pronounced up-
regulation of IRF-1 mRNA in the postischemic brain (Fig.
1). IRF-1 mRNA expression was increased by 12 h and re-
mained elevated 1–7 d after MCA occlusion (
 
P
 
 , 
 
0.05
from sham-operated mice; analysis of variance and Tukey’s
test). IRF-1 mRNA expression did not increase in the
contralateral (nonischemic) cortex (
 
P
 
 . 
 
0.05) (Fig. 1).
IRF-1 mRNA expression was reduced in IRF-1
 
1/2
 
 mice
and absent in IRF-1
 
2/2
 
 mice (Fig. 2).
 
Volume of Ischemic Injury in C57BL/6 and IRF-1 Mice.
 
In these experiments we used mice with a null mutation of
IRF-1 to determine whether IRF-1 contributes to cerebral
ischemic injury. In C57BL/6 mice (
 
n
 
 
 
5 
 
6), MCA occlu-
sion produced reproducible infarcts involving mainly the
cerebral cortex (Figs. 3 and 4). Size and regional distribu-
tion of the infarct were comparable to those previously re-
ported in mice from this and other laboratories (20, 41).
The volume of the infarct in IRF-1
 
1/1
 
 mice did not differ
from that of C57BL/6 mice (
 
P
 
 
 
. 
 
0.05; Fig. 4 A). Infarct
volumes in IRF-1 knockout mice were smaller than those
observed in C57BL/6 mice (Figs. 3 and 4). The reduction
Figure 1. (A) Time course of IRF-1 mRNA expression in mouse ce-
rebral cortex after MCA occlusion. Levels of IRF-1 mRNA were deter-
mined by reverse transcription PCR in samples of cerebral cortex ipsilat-
eral (h) or contralateral to the occluded MCA (n 5 6–12/time point).
mRNA data were normalized to the housekeeping gene HPRT, and are
expressed as fold-induction (mean 6 SEM) relative to unoperated mice.
Since no major differences in IRF-1 mRNA were observed in sham-
operated mice killed 12 h and 1, 2, 4, and 7 d after sham operation (n 5
1–2/time point), mRNA data from all sham-operated mice were aver-
aged. After MCA occlusion IRF-1 mRNA was markedly upregulated in
the ischemic cortex but not contralaterally (*P , 0.05 from contralateral
side; Student’s t test). (B) A representative Southern blot from the isch-
emic side of untreated, sham-operated, and MCA-occluded mice (n 5
3/group) is shown. Analysis of mRNA for the housekeeping gene HPRT
showed no difference among groups in the level of expression (data not
shown; see also Fig. 2 A).
Figure 2. IRF-1 mRNA expression in cerebral cortex of C57BL/6, IRF-
11/2 and IRF-12/2 mice 4 d after MCA occlusion. Levels of IRF-1 mRNA
were determined as described in the legend to Fig. 1. (A) Representative
Southern blot with three individual mice per group illustrating IRF-1
mRNA expression in wild-type, IRF-11/2, and IRF-12/2 mice. mRNA for
the housekeeping gene HPRT is shown as a control. (B) Group data illus-
trating IRF-1 mRNA expression in C57BL/6, IRF-11/2, and IRF-12/2
mice. Means (n 5 5/group) are expressed as fold increase relative to the re-
sponse observed in the nonischemic side (j) of C57BL/6 mice. IRF-1
mRNA is reduced in IRF-11/2 mice and is absent in IRF-12/2. 
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was less pronounced in IRF-1
 
1/2
 
 (23 
 
6 
 
3%;
 
 P 
 
, 
 
0.05;
 
 n 
 
5
 
5), than in IRF-1
 
2/2 mice (46 6 9%; P , 0.05; n 5 6),
and involved the infarct border throughout the entire ros-
trocaudal extent of the ischemic lesion (Figs. 3 and 4). The
volume of postischemic brain swelling did not differ be-
tween C57BL/6 (6.6 6 0.6 mm3) and IRF-11/2 mice (5.7 6
0.8; P . 0.05), but was significantly reduced in IRF-12/2
mice (3.5 6 0.8; P , 0.05).
Neurological Deficits in C57BL/6 and IRF-1 Mice. To
determine whether the reduction in infarct volume was as-
sociated with a better functional outcome, the neurological
deficits produced by MCA occlusion were scored in
C57BL/6 and IRF-12/2 mice. 24 h after MCA occlusion,
neurological deficits did not differ between C57BL/6,
IRF-11/2, and IRF-12/2 mice (Fig. 5). However, although
the deficits in C57BL/6 remained stable throughout the
monitoring period, the deficit in IRF-12/2 mice improved
over time (Fig. 5). By 4 d after MCA occlusion, the motor
impairment was less pronounced in the IRF-11/2 and IRF-
12/2 mice than in C57BL/6 (P , 0.05), the improvement
being more marked in IRF2/2 than in IRF-11/2 mice (Fig.
5). These data indicate that the functional outcome of cere-
bral ischemia is improved in IRF-11/2 and IRF-12/2 mice.
Effect of MCA Occlusion and Hypercapnia on CBF in
C57BL/6 and IRF-1 Mice. In these studies we investi-
gated whether the reduction in CBF produced by MCA
occlusion was comparable in IRF-12/2 mice and controls.
As illustrated in Fig. 6 A, the reduction in CBF produced
by MCA occlusion in IRF-12/2 mice was not different
from that observed in C57BL/6 (P . 0.05; n 5 5–8/
group). Similarly, systemic arterial pressure did not differ
between IRF-12/2 mice and controls (Fig. 6 B). We then
studied the reactivity of the cerebral circulation to systemic
hypercapnia in IRF-12/2 mice. The increase in CBF pro-
duced by hypercapnia (arterial pC02 5 50–60 mmHg) was
73 6 12% of control in C57BL/6 and 61 6 8% in IRF-12/2
mice (P . 0.05; n 5 5/group). Thus, the degree of CBF
reduction produced by MCA occlusion and the reactivity
of the cerebral circulation to hypercapnia are not signifi-
cantly altered in IRF-12/2 mice.
Discussion
We sought to determine whether IRF-1, a transcription
factor involved in tissue responses to inflammation, cell
proliferation, and programmed cell death, is involved in the
Figure 3. Distribution of the cerebral infarct produced by MCA occlu-
sion in C57BL/6 mice and in IRF-11/2 and IRF-12/2 mice 4 d after
MCA occlusion. Thionin-stained representative sections at three different
rostrocaudal levels of the mouse brain are presented. The pale areas with
asterisks represent the infarcted brain. The infarct size is smaller in IRF-
12/2 than in IRF-11/2 or C57BL/6 at all rostrocaudal levels.
Figure 4. Infarct volume in C57BL/6 and IRF-1 mice 4 d after MCA
occlusion. (A) Total infarct volume and infarct volume in neocortex and
striatum are presented. Neocortex (E.C.) indicates neocortical infarct vol-
ume corrected for swelling (see Materials and Methods for details). Infarct
volume (total, neocortex, and striatum) does not differ between C57BL/6
and IRF-11/1 mice (P . 0.5 analysis of variance and Tukey’s test). How-
ever, infarct volume is smaller in IRF-11/2 and IRF-12/2 mice (*P ,
0.05 from C57BL/6). (B) Rostrocaudal distribution of the area of infarc-
tion in the brain of C57BL/6 mice and IRF-11/2 and IRF-12/2 mice 4 d
after MCA occlusion. The reduction in infarct area is greatest in IRF-12/2
and is distributed equally at all rostrocaudal levels (*P  ,  0.05 from
C57BL/6; analysis of variance and Tukey’s test).723 Iadecola et al.
mechanisms of cerebral ischemic injury. We found that
IRF-1 mRNA expression is selectively upregulated in the
ischemic brain after occlusion of the mouse MCA. The up-
regulation is observed within 12 h of induction of ischemia
and is still present at 7 d. To determine whether the IRF-1
mRNA expression contributes to ischemic brain damage,
the infarct volume produced by MCA occlusion was as-
sessed in mice with a null mutation of the IRF-1 gene. We
found that the volume of brain injury produced by MCA
occlusion is markedly reduced in mice with a null mutation
of the IRF-1 gene. The reduction is more pronounced in
IRF-12/2 than in IRF-11/2 mice and, importantly, is asso-
ciated with an improvement of the neurological deficits
produced by the ischemic insult. The findings demonstrate
that IRF-1 is upregulated after induction of cerebral
ischemia and that such upregulation plays a critical role in
the mechanisms of ischemic brain injury.
Several transcription factors have been shown to be acti-
vated after cerebral ischemia. For example, activator pro-
tein 1, factors encoded by early genes, Stat3, hypoxia in-
ducible factor 1, and nuclear factor kb are upregulated after
focal or global cerebral ischemia (29–32). However, direct
evidence for an involvement of these transcription factors
in the mechanisms of ischemic brain injury is lacking (for
example see reference 33). In the present study, we have
demonstrated that deletion of IRF-1 reduces the magni-
tude of cerebral ischemic damage and improves neurologi-
cal recovery. Therefore, IRF-1 is the first transcription fac-
tor that has been shown to be linked directly to the
development of ischemic brain injury.
Like most mice generated by homologous recombina-
tion, the genetic background of IRF-12/2 is heteroge-
neous, including both C57BL/6 and SV129 genes (44).
However, such genetic heterogeneity is unlikely to con-
tribute to the observed reduction in infarct volume. This
conclusion is supported by the following observations.
First, the infarct volume of IRF-11/1 mice, bred from the
same heterozygotic stock from which the homozygous
knockouts were derived, was not different from that of in-
bred wild-type C57BL/6 controls. Second, a clear gene
dosage effect is observed when wild-type, IRF-11/2, and
IRF-12/2 mice are compared for IRF-1 mRNA or infarct
volume. The reduction in infarct volume cannot be attrib-
uted to differences in the degree of cerebral ischemia
Figure 5. Neurological deficits in C57BL/6, IRF-11/2, and IRF-12/2
mice after MCA occlusion. Deficits were quantified according to a neu-
rological scale widely used in mice (see Materials and Methods). Deficits
were identical in all groups 24 h after MCA occlusion. At 3 and 4 d after
MCA occlusion deficits were significantly smaller in IRF-11/2 and IRF-
12/2 mice than in C57BL/6 mice (*P , 0.05, Kruskal-Wallis analysis of
variance and Tukey’s test).
Figure 6. (A) Effect of MCA occlusion on CBF in C57BL/6 mice and
in IRF-12/2. CBF was measured by laser-Doppler flowmetry in the cere-
bral cortex of anesthetized artificially ventilated mice (n 5 5–8/group)
with monitoring of arterial pressure and controlled arterial blood gases
(see Materials and Methods for details). CBF recordings were made in the
center of the ischemic territory, both where the CBF reduction was
greatest (core) and toward the edge of the ischemic area (periphery).
MCA occlusion produces reduction in CBF that are comparable in
C57BL/6 and in IRF-12/2 mice in both the ischemic core and the pe-
riphery (P . 0.05). (B) Mean arterial pressure in wild-type and IRF-12/2
mice before and after MCA occlusion. No significant differences in arte-
rial pressure were observed (P . 0.05).724 Interferon Regulatory Factor 1 and Ischemic Brain Injury
between C57BL/6 and IRF-12/2 mice: MCA occlusion
produced comparable decreases in CBF in wild-type and
IRF-12/2 mice. Furthermore, arterial pressure and the re-
activity of the cerebral circulation to the vasodilation pro-
duced by hypercapnia were not altered in IRF-12/2 mice.
Therefore, genetic factors affecting the susceptibility of the
brain to cerebral ischemia or vascular factors influencing
the degree of ischemia cannot be responsible for the pro-
tection observed in IRF-12/2 mice.
After induction of cerebral ischemia, the temporal evo-
lution of the ensuing brain damage is heterogeneous. In the
center of the ischemic territory, where the ischemic insult
is most severe, irreversible neuronal damage occurs rapidly
(45, 46). Pathogenic factors involved in the rapid phase of
the damage include energy failure, glutamate excitotoxic-
ity, and reactive oxygen species (47–49). In the peripheral
regions of the ischemic territory, the damage progresses at a
slower pace, reaching a maximum 2–3 d after induction of
ischemia (46, 50). Factors contributing to the delayed evo-
lution of the damage include postischemic inflammation
and apoptosis (1, 51). The observation that mice lacking
the IRF-1 gene are relatively protected from ischemic in-
farction suggests that IRF-1 is involved in the mechanisms
of ischemic brain injury. However, the delayed time course
of its expression suggests that this transcription factor is in-
volved mainly in events occurring in the late stages of cere-
bral ischemia. The observation that neurological deficits in
IRF-12/2 mice are not different from those of wild-type
mice 24 h after ischemia and improve 3–4 d later is also
consistent with the hypothesis that IRF-1 contributes to
the progression, rather than the initiation, of tissue damage.
IRF-1 deletion could attenuate the progression of isch-
emic brain injury by different mechanisms. One possibility
is that IRF-1 deletion interferes with the inflammatory re-
sponse associated with cerebral ischemia. Cerebral ischemia
induces an inflammatory reaction in the injured brain (15–
17). Cytokines produced in the ischemic tissue are one of
the factors that induce the expression of adhesion molecules
in endothelial cells (9–12). Blood-borne neutrophils adhere
to the cerebral endothelium, cross the blood vessel wall, and
migrate into the brain parenchyma (13, 14, 17). Neutrophils
contribute to ischemic brain injury because tissue damage is
reduced if their invasion of the brain parenchyma is pre-
vented (52–55; for review see reference 1). After cerebral
ischemia, neutrophils express iNOS, an enzyme that pro-
duces toxic amounts of NO (18–20). Evidence suggests that
NO produced by iNOS participates in ischemic brain in-
jury. Administration of inhibitors of iNOS reduces ischemic
damage, whereas iNOS2/2 mice have smaller infarcts and a
better neurological outcome after MCA occlusion (19, 20,
56). Because IRF-1 plays a role in iNOS transcription (37,
57, 58), it is possible that iNOS is not expressed in IRF-12/2
mice. Therefore, reduced iNOS expression could be one of
the mechanisms by which IRF-12/2 mice are protected
from cerebral ischemia. On the other hand, the possibility
that postischemic iNOS expression is driven by nuclear fac-
tor kB and hypoxia inducible factor 1, transcription factors
that are also upregulated after cerebral ischemia (30, 32),
cannot be ruled out.
Another potential mechanism for the reduction of isch-
emic injury in IRF-12/2 mice is inhibition of programmed
cell death. There is increasing evidence that programmed
cell death occurs after focal cerebral ischemia (for review see
reference 51). Genes involved in the apoptotic cascade are
upregulated after cerebral ischemia (23–26), and internucleo-
somal DNA fragmentation, one of the hallmarks of apopto-
sis, occurs (59–62). Several lines of evidence suggest that ap-
optosis plays a pivotal role in the mechanisms of brain injury.
Transgenic mice that overexpress the anti-apoptotic protein
bcl2 or mice with a null mutation of p53, a protein that pro-
motes apoptosis, are relatively protected from the effects of
focal ischemia (63, 64). In addition, inhibition of the caspase
family of cysteine proteases, one of the effectors of apoptotic
cell death, reduces cerebral ischemic damage (65–67). There
is evidence that IRF-1 is involved in the molecular mecha-
nisms of apoptosis. For example, DNA damage-induced ap-
optosis is attenuated in T-lymphocytes and in macrophages
lacking IRF-1 (68, 69). Therefore, it is conceivable that post-
ischemic apoptotic neuronal death is attenuated in IRF-12/2
mice resulting in less brain damage.
The mechanisms of IRF-1 expression after cerebral isch-
emia and its cellular localization have not been elucidated.
In other systems, IRF-1 is induced by a wide variety of fac-
tors including IFNs and cytokines (34). Some of these fac-
tors, such as IL-1, IL-6 and TNF-a, are also expressed after
cerebral ischemia (4–6) and could conceivably trigger
IRF-1 mRNA expression. Furthermore, intracellular sec-
ond messengers, such as calcium and protein kinase C, may
also induce IRF-1 expression (70). These pathways are ac-
tivated after cerebral ischemia (for examples see references
71, 72) and could contribute to trigger IRF-1 expression.
Therefore, multiple mechanisms are likely to contribute to
IRF-1 upregulation. Further studies will be required to ad-
dress these issues.
In conclusion, we have demonstrated that the mRNA
encoding for the transcription factor IRF-1 is markedly up-
regulated after focal cerebral ischemia. We have also shown
that IRF-12/2 mice are substantially protected from the
brain damage and neurological deficits produced by MCA
occlusion. The protection develops 2–3 d after induction
of ischemia. The findings suggest that IRF-1–inducible
genes contribute to the late stages of tissue damage after ce-
rebral ischemia. Thus, IRF-1 is a critical transcription fac-
tor in the molecular mechanisms of ischemic brain injury
and, as such, might be a new target for therapeutic inter-
ventions in ischemic stroke.
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